Thermo Fisher Scientific Inc. (0R0H.L)
USD 444.49
(-5.68%)
USD 444.49
(-5.68%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 5.08 Billion USD | -9.69% |
| 2022 | 5.63 Billion USD | 11.54% |
| 2021 | 5.05 Billion USD | 25.37% |
| 2020 | 4.02 Billion USD | 19.55% |
| 2019 | 3.37 Billion USD | 12.15% |
| 2018 | 3 Billion USD | 1.14% |
| 2017 | 2.97 Billion USD | 34.25% |
| 2016 | 2.21 Billion USD | 11.11% |
| 2015 | 1.99 Billion USD | 7.11% |
| 2014 | 1.85 Billion USD | 24.42% |
| 2013 | 1.49 Billion USD | 3.55% |
| 2012 | 1.44 Billion USD | 6.49% |
| 2011 | 1.35 Billion USD | 15.34% |
| 2010 | 1.17 Billion USD | 3.86% |
| 2009 | 1.13 Billion USD | -3.41% |
| 2008 | 1.17 Billion USD | 0.13% |
| 2007 | 1.16 Billion USD | 0.47% |
| 2006 | 1.16 Billion USD | 224.01% |
| 2005 | 359.39 Million USD | 6.74% |
| 2004 | 336.71 Million USD | -2.05% |
| 2003 | 343.75 Million USD | 3.29% |
| 2002 | 332.8 Million USD | -1.25% |
| 2001 | 337 Million USD | -14.47% |
| 2000 | 394 Million USD | 5.63% |
| 1999 | 373 Million USD | -37.83% |
| 1998 | 600 Million USD | 10.29% |
| 1997 | 544 Million USD | 25.64% |
| 1996 | 433 Million USD | 36.16% |
| 1995 | 318 Million USD | 36.25% |
| 1994 | 233.4 Million USD | 21.06% |
| 1993 | 192.8 Million USD | 15.31% |
| 1992 | 167.2 Million USD | 43.4% |
| 1991 | 116.6 Million USD | -3.64% |
| 1990 | 121 Million USD | 73.6% |
| 1989 | 69.7 Million USD | 13.52% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 5.43 Billion USD | 4.46% |
| 2024 Q1 | 5.13 Billion USD | 0.88% |
| 2024 Q2 | 5.19 Billion USD | 1.27% |
| 2023 Q1 | 5.66 Billion USD | 0.53% |
| 2023 Q3 | 5.4 Billion USD | -4.44% |
| 2023 FY | 5.08 Billion USD | -9.69% |
| 2023 Q2 | 5.65 Billion USD | -0.16% |
| 2023 Q4 | 5.08 Billion USD | -5.85% |
| 2022 Q1 | 5.48 Billion USD | 8.55% |
| 2022 FY | 5.63 Billion USD | 11.54% |
| 2022 Q4 | 5.63 Billion USD | -1.54% |
| 2022 Q3 | 5.72 Billion USD | 0.95% |
| 2022 Q2 | 5.66 Billion USD | 3.37% |
| 2021 Q3 | 4.9 Billion USD | 6.08% |
| 2021 Q4 | 5.05 Billion USD | 2.96% |
| 2021 Q1 | 4.34 Billion USD | 7.77% |
| 2021 FY | 5.05 Billion USD | 25.37% |
| 2021 Q2 | 4.62 Billion USD | 6.52% |
| 2020 Q2 | 3.64 Billion USD | 5.62% |
| 2020 Q3 | 3.82 Billion USD | 4.96% |
| 2020 Q4 | 4.02 Billion USD | 5.22% |
| 2020 FY | 4.02 Billion USD | 19.55% |
| 2020 Q1 | 3.45 Billion USD | 2.49% |
| 2019 Q4 | 3.37 Billion USD | 1.87% |
| 2019 FY | 3.37 Billion USD | 12.15% |
| 2019 Q1 | 3.12 Billion USD | 3.96% |
| 2019 Q3 | 3.3 Billion USD | 3.09% |
| 2019 Q2 | 3.2 Billion USD | 2.72% |
| 2018 Q3 | 2.98 Billion USD | 4.05% |
| 2018 Q4 | 3 Billion USD | 0.77% |
| 2018 FY | 3 Billion USD | 1.14% |
| 2018 Q1 | 2.89 Billion USD | -2.69% |
| 2018 Q2 | 2.86 Billion USD | -0.86% |
| 2017 Q1 | 2.32 Billion USD | 5.16% |
| 2017 FY | 2.97 Billion USD | 34.25% |
| 2017 Q3 | 3.12 Billion USD | 29.04% |
| 2017 Q4 | 2.97 Billion USD | -4.94% |
| 2017 Q2 | 2.42 Billion USD | 4.09% |
| 2016 Q1 | 2.15 Billion USD | 8.19% |
| 2016 Q2 | 2.08 Billion USD | -3.18% |
| 2016 Q3 | 2.39 Billion USD | 14.6% |
| 2016 Q4 | 2.21 Billion USD | -7.44% |
| 2016 FY | 2.21 Billion USD | 11.11% |
| 2015 Q3 | 1.98 Billion USD | 1.27% |
| 2015 FY | 1.99 Billion USD | 7.11% |
| 2015 Q1 | 1.89 Billion USD | 2.11% |
| 2015 Q2 | 1.96 Billion USD | 3.34% |
| 2015 Q4 | 1.99 Billion USD | 0.23% |
| 2014 Q4 | 1.85 Billion USD | -2.83% |
| 2014 Q3 | 1.91 Billion USD | -1.04% |
| 2014 Q2 | 1.93 Billion USD | -6.15% |
| 2014 Q1 | 2.06 Billion USD | 37.87% |
| 2014 FY | 1.85 Billion USD | 24.42% |
| 2013 Q1 | 1.47 Billion USD | 2.17% |
| 2013 Q4 | 1.49 Billion USD | -3.38% |
| 2013 Q3 | 1.54 Billion USD | 4.01% |
| 2013 Q2 | 1.48 Billion USD | 0.85% |
| 2013 FY | 1.49 Billion USD | 3.55% |
| 2012 FY | 1.44 Billion USD | 6.49% |
| 2012 Q4 | 1.44 Billion USD | -4.86% |
| 2012 Q3 | 1.51 Billion USD | 9.08% |
| 2012 Q1 | 1.42 Billion USD | 4.94% |
| 2012 Q2 | 1.39 Billion USD | -2.22% |
| 2011 FY | 1.35 Billion USD | 15.34% |
| 2011 Q4 | 1.35 Billion USD | -3.61% |
| 2011 Q3 | 1.4 Billion USD | 4.12% |
| 2011 Q2 | 1.35 Billion USD | 6.84% |
| 2011 Q1 | 1.26 Billion USD | 7.57% |
| 2010 Q1 | 1.15 Billion USD | 2.05% |
| 2010 FY | 1.17 Billion USD | 3.86% |
| 2010 Q3 | 1.2 Billion USD | 5.15% |
| 2010 Q4 | 1.17 Billion USD | -2.7% |
| 2010 Q2 | 1.14 Billion USD | -0.53% |
| 2009 FY | 1.13 Billion USD | -3.41% |
| 2009 Q2 | 1.18 Billion USD | 2.01% |
| 2009 Q1 | 1.16 Billion USD | -0.83% |
| 2009 Q4 | 1.13 Billion USD | -3.27% |
| 2009 Q3 | 1.16 Billion USD | -1.31% |
| 2008 Q2 | 1.26 Billion USD | 1.4% |
| 2008 Q1 | 1.24 Billion USD | 6.56% |
| 2008 FY | 1.17 Billion USD | 0.13% |
| 2008 Q3 | 1.26 Billion USD | -0.29% |
| 2008 Q4 | 1.17 Billion USD | -7.06% |
| 2007 Q2 | 1.18 Billion USD | 0.23% |
| 2007 Q1 | 1.18 Billion USD | 1.38% |
| 2007 FY | 1.16 Billion USD | 0.47% |
| 2007 Q3 | 1.2 Billion USD | 1.94% |
| 2007 Q4 | 1.16 Billion USD | -3.01% |
| 2006 FY | 1.16 Billion USD | 224.01% |
| 2006 Q3 | 407.47 Million USD | 2.86% |
| 2006 Q1 | 381.5 Million USD | 6.15% |
| 2006 Q2 | 396.16 Million USD | 3.84% |
| 2006 Q4 | 1.16 Billion USD | 185.78% |
| 2005 Q4 | 359.39 Million USD | -9.14% |
| 2005 Q1 | 345.6 Million USD | 2.64% |
| 2005 FY | 359.39 Million USD | 6.74% |
| 2005 Q2 | 399.69 Million USD | 15.65% |
| 2005 Q3 | 395.55 Million USD | -1.04% |
| 2004 Q2 | 323.87 Million USD | -11.08% |
| 2004 Q1 | 364.23 Million USD | 5.96% |
| 2004 Q3 | 331.14 Million USD | 2.25% |
| 2004 FY | 336.71 Million USD | -2.05% |
| 2004 Q4 | 336.71 Million USD | 1.68% |
| 2003 FY | 343.75 Million USD | 3.29% |
| 2003 Q1 | 342.24 Million USD | 2.84% |
| 2003 Q2 | 343.27 Million USD | 0.3% |
| 2003 Q3 | 338.43 Million USD | -1.41% |
| 2003 Q4 | 343.75 Million USD | 1.57% |
| 2002 Q1 | 342 Million USD | 1.48% |
| 2002 Q2 | 360 Million USD | 5.26% |
| 2002 Q4 | 332.8 Million USD | -5.72% |
| 2002 Q3 | 353 Million USD | -1.94% |
| 2002 FY | 332.8 Million USD | -1.25% |
| 2001 FY | 337 Million USD | -14.47% |
| 2001 Q4 | 337 Million USD | -13.81% |
| 2001 Q3 | 391 Million USD | 0.27% |
| 2001 Q2 | 389.95 Million USD | -3.75% |
| 2001 Q1 | 405.15 Million USD | 2.83% |
| 2000 Q4 | 394 Million USD | 7.61% |
| 2000 Q1 | 388 Million USD | 6.01% |
| 2000 Q2 | 408 Million USD | 5.15% |
| 2000 Q3 | 366.14 Million USD | -10.26% |
| 2000 FY | 394 Million USD | 5.63% |
| 1999 Q2 | 646 Million USD | -5.56% |
| 1999 Q4 | 366 Million USD | -42.9% |
| 1999 Q3 | 641 Million USD | -0.77% |
| 1999 Q1 | 684 Million USD | 106.65% |
| 1999 FY | 373 Million USD | -37.83% |
| 1998 Q2 | 599 Million USD | 6.58% |
| 1998 Q3 | 619 Million USD | 3.34% |
| 1998 Q1 | 562 Million USD | 3.31% |
| 1998 FY | 600 Million USD | 10.29% |
| 1998 Q4 | 331 Million USD | -46.53% |
| 1997 Q2 | 535 Million USD | 4.7% |
| 1997 Q3 | 522 Million USD | -2.43% |
| 1997 Q4 | 544 Million USD | 4.21% |
| 1997 FY | 544 Million USD | 25.64% |
| 1997 Q1 | 511 Million USD | 18.01% |
| 1996 Q3 | 441 Million USD | -1.78% |
| 1996 Q4 | 433 Million USD | -1.81% |
| 1996 FY | 433 Million USD | 36.16% |
| 1996 Q1 | 423 Million USD | 27.03% |
| 1996 Q2 | 449 Million USD | 6.15% |
| 1995 Q3 | 308.1 Million USD | 8.87% |
| 1995 Q1 | 256 Million USD | 9.68% |
| 1995 Q2 | 283 Million USD | 10.55% |
| 1995 Q4 | 333 Million USD | 8.08% |
| 1995 FY | 318 Million USD | 36.25% |
| 1994 FY | 233.4 Million USD | 21.06% |
| 1994 Q3 | 242 Million USD | 1.26% |
| 1994 Q4 | 233.4 Million USD | -3.55% |
| 1994 Q2 | 239 Million USD | 2.14% |
| 1994 Q1 | 234 Million USD | 21.37% |
| 1993 Q2 | 187.8 Million USD | 4.8% |
| 1993 Q1 | 179.2 Million USD | 7.18% |
| 1993 Q4 | 192.8 Million USD | 0.63% |
| 1993 FY | 192.8 Million USD | 15.31% |
| 1993 Q3 | 191.6 Million USD | 2.02% |
| 1992 Q1 | 118.2 Million USD | 1.37% |
| 1992 Q2 | 126.8 Million USD | 7.28% |
| 1992 Q4 | 167.2 Million USD | 3.08% |
| 1992 FY | 167.2 Million USD | 43.4% |
| 1992 Q3 | 162.2 Million USD | 27.92% |
| 1991 Q1 | 121 Million USD | 0.0% |
| 1991 Q3 | 118.2 Million USD | -0.59% |
| 1991 Q4 | 116.6 Million USD | -1.35% |
| 1991 FY | 116.6 Million USD | -3.64% |
| 1991 Q2 | 118.9 Million USD | -1.74% |
| 1990 Q3 | 136.7 Million USD | 4.91% |
| 1990 FY | 121 Million USD | 73.6% |
| 1990 Q1 | 76.3 Million USD | 9.47% |
| 1990 Q2 | 130.3 Million USD | 70.77% |
| 1990 Q4 | 121 Million USD | -11.49% |
| 1989 FY | 69.7 Million USD | 13.52% |
| 1989 Q3 | 71.2 Million USD | 0.0% |
| 1989 Q4 | 69.7 Million USD | -2.11% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -42215.369% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -26572.258% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -8423.184% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -52321.183% |
| bluebird bio, Inc. | 22.91 Million USD | -22099.921% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -180261.574% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -1218.596% |
| Myriad Genetics, Inc. | 20.1 Million USD | -25213.433% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -13184.595% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -6472.964% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 38.846% |
| Waters Corporation | 516.23 Million USD | -885.596% |
| Biogen Inc. | 2.52 Billion USD | -101.314% |
| Nektar Therapeutics | 16.1 Million USD | -31500.522% |
| Perrigo Company plc | 1.14 Billion USD | -345.964% |
| Dynavax Technologies Corporation | 53.29 Million USD | -9447.758% |
| Illumina, Inc. | 587 Million USD | -766.78% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -48955.148% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -11982.641% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | -359.545% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -46162.957% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | -97.171% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -7653.379% |
| FibroGen, Inc. | 41.56 Million USD | -12141.068% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -393.501% |
| OPKO Health, Inc. | 65.69 Million USD | -7644.646% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -5607.491% |
| Exelixis, Inc. | 17.32 Million USD | -29271.356% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | -98.44% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -33517.443% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 208283.306% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -588.684% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -17799.736% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -1475.92% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -65721.475% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -3887.43% |
| Blueprint Medicines Corporation | 21.22 Million USD | -23873.99% |
| Insmed Incorporated | 83.24 Million USD | -6011.859% |
| TG Therapeutics, Inc. | 39.82 Million USD | -12676.536% |
| Incyte Corporation | 62.97 Million USD | -7979.781% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -1446.975% |